Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease

Movement Disorders

Volumn 15, Issue 1, 2000, Pages 30-35

  Bandmann, Oliver ^a   Vaughan, Jenny R ^a   Holmans, Peter ^b   Marsden, C David ^a   Wood, Nicholas W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Detoxification; Familial Parkinson's disease; Genetics; N acetyltransferase 2

Indexed keywords

ACYLTRANSFERASE; MUTANT PROTEIN;

ACETYLATION; ALLELE; ARTICLE; CONTROLLED STUDY; GENETIC LINKAGE; GENOTYPE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL;

ACETYLATION; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BRAIN; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOTYPE; HUMANS; HUNTINGTON DISEASE; PARKINSON DISEASE;

EID: 0033957962     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200001)15:1<30::AID-MDS1007>3.0.CO;2-V     Document Type: Article

References (24)

1. Polymeropoulos M, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
2. Gasser T, Müller-Myhsok B, Wszolek Z, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998;18:262-265.
3. Tanner C, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-664.
4. Semchuk K, Love E, Lee R. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-1180.
5. Seidler A, Hellenbrand W, Robra B-P, et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case control study in Germany. Neurology 1996;46:1275-1284.
6. Tanner C. Epidemiological clues to the cause of Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders 3. London: Butterworth-Heinemann, 1994:124-146.
7. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. The slow acetylator genotype for N-acetyltransferase 2 is associated with familial Parkinson's disease. Lancet 1997;350:1136-1139.
8. Bell D, Taylor J, Butler M, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993;14:1689-1692.
9. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-592.
10. Vatsis K, Weber W, Bell D, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
11. Maraganore D, Harding A, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991;6:205-211.
12. Payami H, Joe S, Farid N, et al. Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet 1989;45:541-546.
13. Risch A, Wallace D, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995;4:231-236.
14. Nicholl D, Bennett P. Acetylator genotype and Parkinson's disease. Lancet 1998;351:141-142.
15. Ladero J, Jimenez F, Benitez J, et al. Acetylator polymorphism in Parkinson's disease. Eur J Clin Pharmacol 1989;37:391-393.
16. Igbokwe E, Ogunniyi A, Osuntokun B. Xenobiotic metabolism in idiopathic Parkinson's disease in Nigerian Africans. East Afr Med J 1993;70:807-809.
17. Peters L, Steventon G, Green S, Sturman S, Waring R, Williams A. D-Penicillamine metabolism in neurodegenerative diseases: an in vivo/in vitro sulphydryl methylation study. Xenobiotica 1994;24: 1013-1020.
18. Snyder S, D'Amato R. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 1986;36:250-258.
19. Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature 1994;369:154-156.
20. Hein D, Weber W. Relationship between N-acetylator phenotype and susceptibility toward hydrazine-induced lethal central nervous system toxicity in the rabbit. J Pharmacol Exp Ther 1984;228: 588-592.
21. Datta U, Noailles P-A, Rodriguez M, Kraft M, Zhang Y, Angulo J. Accumulation of tyrosine hydroxylase messenger RNA molecules in the rat mesencephalon by chronic caffeine treatment. Neurosci Lett 1996;220:77-80.
22. O'Donohue T, Handelmann G, Miller R, Jacobowitz D. N-acetylation regulates the behavioral activity of alpha-melanotropin in a multineurotransmitter neuron. Science 1982;215:1125-1127.
23. Youdim M, Riederer P. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Mov Disord 1993;8:S8-S13.
24. Gilad G, Gilad V. Polyamines can protect against ischemia-induced nerve cell death in gerbil forebrain. Exp Neurol 1991;111: 349-355.